Lexicon Pharmaceuticals | LXRX - Assets


Lexicon Pharmaceuticals reported $225.58M in Assets for its fiscal quarter ending in June of 2025.





Assets Change Date
Abbott USD 86.71B 2.53B Dec/2025
Acadia Pharmaceuticals USD 1.56B 233.42M Dec/2025
Agios Pharmaceuticals USD 1.3B 88.48M Dec/2025
Akebia Therapeutics USD 376.56M 12.41M Dec/2025
Alnylam Pharmaceuticals USD 4.97B 114.67M Dec/2025
AstraZeneca USD 114.07B 382M Dec/2025
BioMarin Pharmaceutical USD 7.59B 20.85M Dec/2025
Coherus Biosciences USD 258.34M 258.18M Dec/2025
Eli Lilly USD 112.48B 2.46B Dec/2025
Esperion Therapeutics USD 364.02M 16.93M Sep/2025
Halozyme Therapeutics USD 2.53B 304.09M Dec/2025
Illumina USD 6.64B 467M Dec/2025
Insmed USD 2.26B 96.18M Dec/2025
Ironwood Pharmaceuticals USD 396.06M 53.12M Sep/2025
J&J USD 199.21B 6.39B Dec/2025
Lexicon Pharmaceuticals USD 225.58M 72.09M Jun/2025
MacroGenics USD 270.76M 25.34M Sep/2025
MannKind USD 792.18M 297.54M Dec/2025
Merck USD 129.55B 12.02B Sep/2025
Moderna USD 12.34B 203M Dec/2025
Novartis USD 107.29B 2.89B Sep/2025
PTC Therapeutics USD 2.9B 255.07M Dec/2025
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Sarepta Therapeutics USD 3.35B 143.73M Dec/2025
Thermo Fisher Scientific USD 110.34B 7.32B Dec/2025
Ultragenyx Pharmaceutical USD 1.53B 341.56M Dec/2025
United Therapeutics USD 7.88B 528.9M Dec/2025
Vanda Pharmaceuticals USD 488.95M 112.19M Dec/2025